Trader_NA schreef op 19 maart 2021 12:31:
Ruconest More Cost-effective Than Other
On-demand Treatments for HAE Attacks, Study Estimates
June 19, 2020
Marisa Wexler, MSby Marisa Wexler, MSangioedemanews.com/2020/06/19/rucones...From this, the overall cost incurred by an insurance plan for Ruconest would be $6.94 million per year, equating to $0.58 per member per month (PMPM). The overall cost of Firazyr was $7.97 million ($0.66 PMPM), of Berinert was $7.90 million ($0.66 PMPM), and of Kalbitor was $11.33 million ($0.94 PMPM).
“The budget impact model demonstrates that on-demand treatment using rhC1-INH [Ruconest] could represent cost savings of more than $1 million per year compared with icatibant [Firazyr] and more than $4 million compared with ecallantide [Kalbitor],” researchers wrote.
“Those figures are outright costs, and when combined with better effectiveness, rhC1-INH may also contribute to a higher quality of life for patients due to a low redose rate,” they added.
Further analysis of the model suggested that the low re-dose rate was a primary driver of Ruconest’s cost-efficacy, particularly in comparison to Firazyr and Berinert, which have comparable costs for the drug itself. The ability to self-administer — as opposed to requiring a healthcare professional to administer, as is the case for Kalbitor — also was a noteworthy factor.
(Note: het plaatje is dit jaar anders vanwege verhoging kosten).